Yale School Of Medicine

Patient-reported outcome measures that assess a range of relevant domains such as health status and quality of life are vital for the comprehensive management of peripheral artery disease, according to a new scientific statement.

Open communication between stakeholders and patient education are two underlying themes in a new series of recommendations provided in a consensus report on the use of automated insulin delivery systems.

Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.

Smilow Cancer Hospital has introduced a new single-port robotic prostatectomy procedure that reduces the number of incisions and may minimize the risk for complications.

The Lupus Research Alliance has awarded the 2022 Lupus Insight Prize to Akiko Iwasaki, PhD, for her work connecting endogenous retroviruses and systemic lupus erythematosus.

Researchers led by a Yale University team have developed a new measure for neoadjuvant chemotherapy efficacy for use in preoperative breast cancer trials.

Results of a phase 1/phase 2 study showed similar treatment outcomes among Black and non-Black women who received durvalumab plus chemotherapy prior to surgery for triple-negative breast cancer.

In this video Michael Cecchini, MD discussed study presented at ASCO that "puts to rest" whether asymptomatic primary tumors in patients with metastatic colorectal cancer should be resected.

Tirzepatide vs. placebo for weight loss in adults with overweight or obesity but without diabetes.

In this video, Michael Cecchini, MD, discussed a late-breaking abstract evaluating FOLFOXIRI plus panitumumab vs. mFOLFOX6 plus panitumumab as initial treatment of unresectable RAS and BRAF wild-type metastatic colorectal cancer.